Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors

NCT04034238 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

19

Enrollment

NIH

Sponsor class

Conditions

Neoplasms With Mesothelin Expression
Epithelioid Mesothelioma
Cholangiocarcinoma, Extrahepatic
Adenocarcinoma, Pancreatic

Interventions

DRUG: LMB-100
DRUG: Tofacitinib
DEVICE: Mesothelin Expression

Sponsor

National Cancer Institute (NCI)